苏丹肝脾型血吸虫病中的药物代谢：一项关于安替比林的研究。
Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.
作者信息
Homeida M, Salih S Y, Branch R A
出版信息
Gut. 1978 Sep;19(9):808-11. doi: 10.1136/gut.19.9.808.
Abstract
The disposition of antipyrine following oral administration of 1200 mg has been investigated in 10 patients with histologically confirmed hepatosplenic schistosomiasis and 11 normal subjects living in Sudan. Drug metabolising activity as assessed by antipyrine clearance was similar in patients when compared with normal controls. We conclude that antipyrine disposition is normal in patients with clinically compensated hepatosplenic schistosomiasis.
摘要
对10例经组织学确诊为肝脾型血吸虫病的患者和11名居住在苏丹的正常受试者口服1200毫克安替比林后的处置情况进行了研究。与正常对照组相比，患者中通过安替比林清除率评估的药物代谢活性相似。我们得出结论，临床代偿性肝脾型血吸虫病患者的安替比林处置情况正常。
相似文献
1
Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.苏丹肝脾型血吸虫病中的药物代谢：一项关于安替比林的研究。
Gut. 1978 Sep;19(9):808-11. doi: 10.1136/gut.19.9.808.
2
Altered drug metabolism in hepatosplenic schistosomiasis.
Rev Inst Med Trop Sao Paulo. 1979 Sep-Oct;21(5):254-9.
3
The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.不同严重程度血吸虫病患者中安替比林的药代动力学
Br J Clin Pharmacol. 1985 Oct;20(4):313-6. doi: 10.1111/j.1365-2125.1985.tb05069.x.
4
Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.口服甲硝唑在肝硬化和肝脾血吸虫病中的处置情况。
Gut. 1982 Oct;23(10):807-13. doi: 10.1136/gut.23.10.807.
5
Propranolol disposition in patients with hepatosplenic schistosomiasis.心得安在肝脾型血吸虫病患者体内的处置情况。
Br J Clin Pharmacol. 1987 Sep;24(3):393-6. doi: 10.1111/j.1365-2125.1987.tb03187.x.
6
Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan.苏丹肝脾型血吸虫病患者中奥沙尼喹的药代动力学
J Antimicrob Chemother. 1987 Jan;19(1):87-93. doi: 10.1093/jac/19.1.87.
7
Pharmacokinetics of cefoperazone in normal subjects and patients with hepatosplenic schistosomiasis.头孢哌酮在正常受试者和肝脾型血吸虫病患者中的药代动力学。
J Antimicrob Chemother. 1983 Oct;12(4):407-10. doi: 10.1093/jac/12.4.407.
8
[Intestinal absorption in the hepatosplenic form of schistosomiasis mansoni].
Rev Hosp Clin Fac Med Sao Paulo. 1971 Apr;26(2):55-60.
9
Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis.
J Hepatol. 1992 May;15(1-2):35-9. doi: 10.1016/0168-8278(92)90008-d.
10
[Plasma clearance of bromsulphalein in patients with the hepatosplenic form of schistosomiasis mansoni].
Rev Hosp Clin Fac Med Sao Paulo. 1979 Apr;34(2):48-53.
引用本文的文献
1
A review of the pharmacokinetic implications of schistosomiasis.血吸虫病药代动力学影响的综述。
Clin Pharmacokinet. 2013 Aug;52(8):647-56. doi: 10.1007/s40262-013-0055-8.
2
The hepatic and duodenal activities of some drug metabolizing enzymes in chickens: influence of infection with Escherichia coli endotoxin and coccidiosis.
Eur J Drug Metab Pharmacokinet. 1997 Jul-Sep;22(3):223-7. doi: 10.1007/BF03189811.
3
Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.口服甲硝唑在肝硬化和肝脾血吸虫病中的处置情况。
Gut. 1982 Oct;23(10):807-13. doi: 10.1136/gut.23.10.807.
4
The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.不同严重程度血吸虫病患者中安替比林的药代动力学
Br J Clin Pharmacol. 1985 Oct;20(4):313-6. doi: 10.1111/j.1365-2125.1985.tb05069.x.
5
Propranolol disposition in patients with hepatosplenic schistosomiasis.心得安在肝脾型血吸虫病患者体内的处置情况。
Br J Clin Pharmacol. 1987 Sep;24(3):393-6. doi: 10.1111/j.1365-2125.1987.tb03187.x.
6
Clinical pharmacokinetics of anthelmintic drugs.抗蠕虫药物的临床药代动力学
Clin Pharmacokinet. 1988 Aug;15(2):67-93. doi: 10.2165/00003088-198815020-00001.
7
Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.苏丹成人肝细胞癌患者氧化代谢的评估
Gut. 1986 Apr;27(4):382-5. doi: 10.1136/gut.27.4.382.
本文引用的文献
1
The fate of antipyrine in man.安替比林在人体内的代谢情况。
J Pharmacol Exp Ther. 1950 Jan;98(1):97-104.
2
PORTAL HEMODYNAMICS AND LIVER CELL FUNCTION IN HEPATIC SCHISTOSOMIASIS.肝血吸虫病的门静脉血流动力学与肝细胞功能
Gastroenterology. 1964 Sep;47:241-7.
3
Metabolism of niridazole in various species, including man.
Ann N Y Acad Sci. 1969 Oct 6;160(2):544-57. doi: 10.1111/j.1749-6632.1969.tb15874.x.
4
A new active metabolite of "Miracil D".
Nature. 1965 Dec 4;208(5014):1005-6. doi: 10.1038/2081005a0.
5
Clearance of antipyrine-dependence of quantitative liver function.安替比林清除率与定量肝功能的相关性
Eur J Clin Invest. 1974 Apr;4(2):129-34. doi: 10.1111/j.1365-2362.1974.tb00383.x.
6
Determinants of serum antipyrine half-lives in patients with liver disease.肝病患者血清安替比林半衰期的决定因素。
Gut. 1973 Jul;14(7):569-73. doi: 10.1136/gut.14.7.569.
7
Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.口服和静脉注射后安替比林、甲苯磺丁脲和华法林的血浆水平比较。
Clin Pharmacol Ther. 1974 Dec;16(6):1059-65. doi: 10.1002/cpt19741661059.
8
Commentary: a physiological approach to hepatic drug clearance.述评：肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.
9
Infection with Schistosoma mansoni in the Gezire area of the Sudan.苏丹杰济拉地区曼氏血吸虫感染情况。
J Trop Med Hyg. 1976 Jul;79(7):151-7.
10
Mutagenic activities in vitro and in vivo of five antischistosomal compounds.
J Pharmacol Exp Ther. 1977 Jan;200(1):1-9.
Zotero 插件